Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
BACKGROUND: Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. OBJECTIVE: To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT random...
Main Authors: | Johnston, T, Shaw, G, Lamb, A, Parashar, D, Greenberg, D, Xiong, T, Edwards, A, Gnanapragasam, V, Holding, P, Herbert, P, Davis, M, Mizielinsk, E, Lane, J, Oxley, J, Robinson, M, Mason, M, Staffurth, J, Bollina, P, Catto, J, Doble, A, Doherty, A, Gillatt, D, Kockelbergh, R, Kynaston, H, Prescott, S, Paul, A, Powell, P, Rosario, D, Rowe, E, Donovan, J, Hamdy, F, Neal, D, ProtecT study group |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2016
|
Similar Items
-
Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
by: Neal, D, et al.
Published: (2019) -
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
by: Hamdy, FC, et al.
Published: (2020) -
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
by: J. Donovan, et al.
Published: (2003-01-01) -
The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
by: Young, GJ, et al.
Published: (2020) -
10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer
by: Hamdy, F, et al.
Published: (2016)